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Binding	  of	  sulfanilamide	  to	  carbonic	  anhydrase.	  Compara8ve	  measurements	  with	  the	  GCI	  prototype	  
QUBE	  CX-­‐3	  (leD)	  and	  the	  SPR-­‐based	  Biacore	  T200	  (right)	  
ka	  /	  (M-­‐1s-­‐1)	   kd	  /	  (s-­‐1)	   KD	  /	  (µM)	  
1.24	  *	  104	   0.100	   8.04	  
ka	  /	  (M-­‐1s-­‐1)	   kd	  /	  (s-­‐1)	   KD	  /	  (µM)	  
2.8	  *	  104	   0.144	   5.15	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The	   main	   advantage	   of	   label-­‐free	   methods	   over	   conven1onal	   methods	  
based	  on	  absorp1on,	  ﬂuorescence	  or	  radioac1vity	   is	  that	  the	  interac1on	  
between	   the	   molecules	   is	   not	   disturbed	   by	   any	   label.	   Furthermore,	  
labeling	   and	   washing	   steps	   are	   not	   needed	   and	   thus	   reducing	   reagent	  
use,	   costs	   and	   1me.	   Compared	   to	   other	   label-­‐free	   sensors	   such	   as	   the	  
ones	   based	   on	   surface	   plasmon	   resonance	   (SPR),	   gra1ng-­‐coupled	  
interferometers	   show	  higher	   sensi1vity	  due	   to	  a	   longer	   interac1on	  with	  
the	   sample	   (some	   millimeters	   compared	   to	   micrometers	   with	   SPR).	   In	  
addi1on,	   their	   evanescent	   ﬁelds	   have	   a	   shorter	   penetra1on	   depth	   of	  
80-­‐100	  nm	  compared	  to	  200-­‐300	  nm	  with	  SPR,	  and	  thus	   interferometric	  
waveguide	  sensors	  are	  less	  sensi1ve	  to	  matrix	  eﬀects	  caused	  by	  changes	  




For	  comparison,	  measurements	  were	  performed	  on	  a	  SPR-­‐based	  Biacore	  
T200	   (GE	  Healthcare),	   currently	   the	  most	  sensi1ve	   label-­‐free	   instrument	  
on	  the	  market.	  The	  determina1on	  of	  the	  binding	  of	  low	  molecular	  weight	  
drug	   candidates	   for	   target	   proteins	   requires	   highest	   sensi1vity.	   The	  GCI	  
prototype	  QUBE	  CX-­‐3	  showed	  equivalent	  kine1c	  data	  as	  Biacore	  T200	  for	  
the	   binding	   of	   sulfanilamide	   (172	   Da)	   to	   carbonic	   anhydrase,	   however	  
with	  an	  about	  4	  fold	  higher	  signal-­‐to-­‐noise	  ra1o	  (see	  ﬁgure	  below).	  	  
Abstract	  
Creop1x	  GmbH	  has	  developed	  a	  novel	  and	  innova1ve	  technology	  for	  label-­‐free	  detec1on	  of	  molecules	  based	  on	  gra1ng-­‐coupled	  interferometry	  (GCI).	  GCI	  is	  a	  
proprietary	  technology	  characterized	  by	  a	  very	  high	  sensi1vity	  at	  low	  technical	  complexity.	  One	  main	  applica1on	  will	  be	  the	  measurement	  of	  binding	  aﬃni1es	  
in	  research	  and	  development	  projects	  such	  as	  drug	  discovery.	  Goal	  of	  an	  interdisciplinary	  CTI	  project	  with	  the	  partners	  from	  ZHAW,	  FHNW	  and	  CSEM	  together	  
with	  Creop1x	  is	  the	  development	  of	  a	  ﬁrst	  GCI	  instrument	  including	  disposables	  and	  the	  op1miza1on	  of	  its	  func1onality,	  followed	  by	  ﬁeld	  tests	  to	  pave	  the	  
way	  to	  market	  introduc1on.	  	  
	  
Conclusion	  
In	   this	   project	   a	   gra1ng-­‐coupled	   interferometer	   with	   highest	   sensi1vity	   was	   successfully	   developed	   in	   collabora1on	   of	   a	   young	   innova1ve	   company	   with	  
universi1es	  of	  applied	  sciences	  and	  the	  CSEM.	  The	  feasibility	  studies	  for	  the	  use	  in	  Life	  Sciences	  will	  help	  to	  pave	  the	  way	  to	  the	  market	  launch	  planned	  for	  end	  
of	  2013.	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Working	   principle	   of	   Creop8x’	   gra8ng-­‐coupled	   interferometer:	  
Central	   element	   is	   a	   chip	   with	   a	   tantalum	   pentoxide	   op1cal	  
waveguide.	   The	   surface	   of	   the	   chip	   is	   func1onalized	   to	   allow	  
immobiliza1on	   of	   ligands	   or	   receptors	   to	   the	   chip.	   Binding	   of	  
analyte	   occurs	   when	   the	   analyte	   is	   passed	   over	   the	   chip	   in	   a	  
microﬂuidic	  system.	  The	  readout	  is	  achieved	  by	  detec1ng	  a	  1me-­‐
dependent	   interference	   signal	   which	   is	   generated	   by	   the	  
superposi1on	   of	   a	   phase-­‐modulated	   reference	   wave	   and	   an	  
unmodulated	   signal	  wave	  within	   the	  waveguide.	   The	  binding	   of	  
the	   analyte	   to	   the	   immobilized	   receptor	   in	   the	  evanescent	  ﬁeld	  
results	  in	  a	  phase	  change	  of	  the	  signal	  wave,	  thereby	  shiping	  the	  
interference	  pa_ern.	  	  
	  
The	   QUBE	   CX-­‐3	   with	   the	   disposable	   chip	   cartridge	   with	  
integrated	   microﬂuidics:	   The	   innova1ve	   integra1on	   of	   the	  
microﬂuidics	   into	  a	  disposable	  cartridge	  will	   lower	  device	  down-­‐
1me	   and	   together	   with	   the	   modern	   sopware	   will	   improve	   the	  
ease	  of	  use	  with	  respect	  to	  exis1ng	  instrumenta1on.	  
The	  GCI	  prototype	  was	  also	  capable	  to	  measure	  the	  very	  high	  aﬃnity	  (KD	  
=	   90	   pM)	   of	   the	   interac1on	   of	   human	   interleukin-­‐1β	   and	   a	  monoclonal	  
an1body	   which	   is	   in	   clinical	   development.	   Importantly,	   for	   this	  
interac1on,	  the	  very	  low	  dissocia1on	  rate	  constant	  (kd	  =	  5.7x10-­‐5	  s-­‐1)	  could	  
reliably	  be	  measured	  on	  the	  GCI	  prototype	  demonstra1ng	  a	  high	  stability	  
of	  the	  instrument.	  	  
